Provided by:
Viral Hepatitis Grand Rounds from the
Perelman School of Medicine at the
University of Pennsylvania
Academic Year 2014-2015
“Developing Synthetic DNA Immune Therapeutic Approaches for Chronic Infectious Agents”
March 4, 2015
12:00 PM (EDT) - 1:00 PM (EDT)
BRB II/III Auditorium
David B. Weiner, PhD
Professor, Department of Pathology and Laboratory Medicine
Chair, Gene Therapy and Vaccine Program, CAMB
Co-Leader Tumor Virology Program, Abramson Cancer Program
University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania
Target Audience
This program has been designed for departmental/institutional faculty, fellows, residents, medical students, nurses,
nurse practitioners, physician assistants and allied health professionals in the medical specialties of infectious disease,
hepatology, gastroenterology, and internal medicine
Educational Objectives
After completing this activity, participants should be able to:
 Demonstrate increased understanding of the epidemiology of and risk factors for viral hepatitis.

Increase the rate of testing for viruses associated with hepatitis.

Demonstrate improved knowledge, competence and clinical practice in terms of the current standards and
guidelines for the management of patients with viral hepatitis.

Demonstrate an improved understanding of the treatment of viral hepatitis in patient co-infected with HIV or
other viral infections.
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA
PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
Acknowledgement of Commercial Support*
Gilead Sciences Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc., Jansen Therapeutics, Division of Janssen
Products, LP, AbbVie Inc., Vertex Pharmaceuticals, Inc.
For more information, please contact
Richard Gordon
847-951-5318
rgorgdon@viraled.com
Check your CME online at www.penncmeonline.com
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the
content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial
interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this
purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in
CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice,
are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all
content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to
contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were
instructed to provide balanced, scientifically rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic, Director of
CME and the peer reviewer Zalman Agus, MD, Associate Dean for CME, have disclosed that they have no relevant financial
relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to
the content of this educational activity:
PLANNING COMMITTEE MEMBER NAME
BRIAN BOYLE
MILA KOSTIC
OLIVER FULTZ
MICHAEL SCHOEN, PHD
RICK GORDON
The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of
this educational activity.
PLANNING COMMITTEE MEMBER NAME
DAVID KAPLAN, MD
IAN FRANK, MD
K. RAJENDER REDDY, MD
MARK SULKOWSKI, MD
NAME OF COMMERCIAL INTEREST
BAYER PHARMACEUTICALS
GILEAD, VIIV
JANSSEN
GLAXOSMITH KLINE, BAVARIAN NORDIC
JANSSEN, MERCK, GENENTECH-ROCHE, GILEAD, BMS, ABBVIE
JANSSEN, MERCK, GILEAD, BMS, ABBVIE
ABBVIE, BMS, GILEAD, MERCK, JANSSEN, BIPI
ABBVIE, BMS, GILEAD, MERCK, JANSSEN, TOBIRA
GILEAD
RELATIONSHIP
RESEARCH SUPPORT
HONORARIUM
CONSULTANT
RESEARCH SUPPORT
HONORARIUM
RESEARCH SUPPORT
RESEARCH SUPPORT
SCIENTIFIC ADVISOR
DSMB
PRESENTER NAME
DAVID B. WEINER, PHD
NAME OF COMMERCIAL INTEREST
RELATIONSHIP
ROCHE
SPEAKER/CONSULTANT
SANOFI, MERCK
SPEAKER
INOVIO*
CONSULTANT/SAB SERVICE
*DR. WEINER HAS RECEIVED STOCK AND ROYALTIES UNDER THE UNIVERSITY OF PENNSYLVANIA PLAN DUE TO LICENSING OF SPECIFIC TECHNOLOGY TO INOVIO.
HE HAS A MANAGEMENT PLAN IN PLACE AS PER UNIVERSITY OF PENNSYLVANIA COI POLICY.
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property
rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial
benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research),
consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is
received or expected
PRESENTER NAME
DAVID B. WEINER, PHD
PRODUCT
INVESTIGATIONAL AND/OR OFF-LABEL USE
MY PRESENTATION WILL DISCUSS DNA VACCINE TECHNOLOGY WHICH IS BEING DEVELOPED BY INOVIO IN PART AS WELL AS
OTHER COMPANIES. THE CLINICAL DEVELOPMENT OF DNA TECHNOLOGY IS ONE ASPECT OF THIS LECTURE.